NovaBridge Picks 8 mg/kg Givastomig Dose After FDA Aligns on Phase 3
NBP is trading near its 52-week low of $1.255 (13% above the low).
Summary
NovaBridge locked in the 8 mg/kg dose for givastomig and said it has FDA alignment on a global registrational study protocol in first-line metastatic gastroesophageal adenocarcinoma. The decision follows mature Phase 1b data presented at ESMO 2026, with manageable safety and no Grade 4/5 treatment-related adverse events when combined with nivolumab and chemotherapy. FDA alignment removes a major design risk from the Phase 3 and clarifies the path to a potential filing; givastomig also carries Fast Track and Orphan Drug designations. This is the clearest late-stage read on the program since the August 6-K laid out the Phase 3 timeline alongside a $216M cash position. The stock is a microcap at $1.42, so a clean Phase 3 design is a meaningful de-risking step, though the actual efficacy readout remains the binary event.
At the time of this announcement, NBP was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $158.9M. The 52-week trading range was $1.26 to $5.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.